Psychological Medicine · Nov 9, 2026

Sodium-glucose cotransporter 2 inhibitors and risk of self-harm in patients with type 2 diabetes mellitus: an active comparator, new user cohort study in two independent cohorts

By Li Y, Zeng H, Wu L et al.

Background: Although type 2 diabetes mellitus (T2DM) has twice the self-harm risk of the general population, the role of sodium-glucose cotransporter 2 inhibitors (SGLT-2i) is unclear; this study aimed to assess whether SGLT-2i use is linked to lower self-harm risk in T2DM. Methods: Through the Shenzhen Public Health Data Platform, we constructed two cohorts (SGLT-2i vs. dipeptidyl peptidase-4 inhibitors [DPP-4i], and SGLT-2i vs. glucagon-like peptide-1 receptor agonists [GLP-1RA]) via a target trial emulation framework. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using overlapping weighting Cox regression models. Results: The SGLT-2i versus DPP-4i cohort included 85,789 SGLT-2i users and 53,810 DPP-4i users. After a median follow-up of 1.85 years (interquartile range: 0.91–2.70), 567 (0.66%) cases of self-harm occurred in the SGLT-2i group and 567 (1.05%) in the DPP-4i group. After overlapping weighting, SGLT-2i was associated with a lower risk of self-harm compared with DPP-4i (HR: 0.86, 95% CI: 0.76–0.98), and this result was consistent across various sensitivity analyses. In the SGLT-2i ( n = 130,330) versus GLP-1RA ( n = 5,126) cohort, a lower risk of self-harm (HR: 0.76, 95% CI: 0.59–0.99) was associated with SGLT-2i compared with GLP-1RA. However, in some sensitivity analyses, no statistically significant difference was observed between SGLT-2i and GLP-1RA users. Conclusions: SGLT-2i use is associated with a lower risk of self-harm compared with DPP-4i and GLP-1RA. These findings provide supportive evidence for the safety of SGLT-2i and highlight their potential role in the mental health management of T2DM patients.

doi.org/10.1017/s0033291726105984Open accessPubMed 43001501Populations

AgingResearch.News